Exactly that's why fattening the sales line with a take out makes alot of sense.
TMO Business plan<-------- Fold em in.
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Exactly that's why fattening the sales line with a take out makes alot of sense.
TMO Business plan<-------- Fold em in.
great news from the vet!!! Bacchus is now on the 1 month plan!
No more infection in the anal gland!
1 month drainage plan.... Just like At&T
No more infection in the anal gland!
1 month drainage plan.... Just like At&T
Van did you say Tractor Supply was a bad pick? I didn't see that you just like HD better.
Some youngster is trying to start trouble sending me an email saying you said TSCO was a bad pick.....
Some youngster is trying to start trouble sending me an email saying you said TSCO was a bad pick.....
Early notable gainers among liquid option names on October 24th 09:55 TSCO, T, HBAN, UHS, FITB Notable gainers among liquid option names this morning include Tractor Supply (TSCO) $206.00 +8.63 
LONGSHOT UPDATE-! Up 6 cents. 
EZFill Holdings Inc. (EZFL)
NasdaqCM - NasdaqCM Real Time Price.
0.6600+0.0295(+4.68%)
As of 10:40AM EDT.
EZFill Holdings Inc. (EZFL)
NasdaqCM - NasdaqCM Real Time Price.
0.6600+0.0295(+4.68%)
As of 10:40AM EDT.
Tesla, Inc. (TSLA)
NasdaqGS - NasdaqGS Real Time Price.
203.90-10.54(-4.92%)
As of 10:55AM EDT.
Van what the hell are we going to do about this? We have to teach the children how to manage risk but this POS is going lower and lower. Are they trapped?
... Or did they flip into IRDM-?
NasdaqGS - NasdaqGS Real Time Price.
203.90-10.54(-4.92%)
As of 10:55AM EDT.
Van what the hell are we going to do about this? We have to teach the children how to manage risk but this POS is going lower and lower. Are they trapped?
... Or did they flip into IRDM-?
Polaris Inc. (PII)- Up $3 since post..... not in.
NYSE - Nasdaq Real Time Price.
95.39+2.66(+2.87%)
As of 10:59AM EDT. Market open.
VERY TEMPTED RIVN-
Rivian Automotive, Inc. (RIVN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
https://finance.yahoo.com/chart/RIVN?studies=Visitor Trend&ncid=dcm_306158729_490172245_127172993
30.00-1.92(-6.02%)<------------
Rivian Automotive, Inc. (RIVN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
https://finance.yahoo.com/chart/RIVN?studies=Visitor Trend&ncid=dcm_306158729_490172245_127172993
30.00-1.92(-6.02%)<------------
So far no action on my ideas to the HF for the upcoming day/week...
Might of been a bum list.
Going to try and make the case for Amylx. Look they just raised money issued shares AND ARE UP!<------ not many bios can pull that off.
Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct. 07, 2022 5:18 AM ET Amylyx Pharmaceuticals, Inc. (AMLX)By:Meghavi Singh,SA News Editor
Might of been a bum list.
Going to try and make the case for Amylx. Look they just raised money issued shares AND ARE UP!<------ not many bios can pull that off.
Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct. 07, 2022 5:18 AM ET Amylyx Pharmaceuticals, Inc. (AMLX)By:Meghavi Singh,SA News Editor
- Amylyx Pharmaceuticals (NASDAQ:AMLX) haspricedan upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00/share.
- All of the shares of common stock are being offered by Amylyx.
- Underwriters are granted a 30-day option to purchase up to an additional 1,004,062 shares of common stock at the public offering price.
- Gross proceeds to Amylyx from this offering are expected to be $214.2M.
Oct 3
Citi ups Amylyx target, sees buying opportunity after selloff 10/03 AMLX Citi analyst Neena Bitritto-Garg raised the firm's price target on Amylyx Pharmaceuticals to $50 from $48 and keeps a Buy rating on the shares. The analyst updated her model on full FDA approval for AMX0035, now Relyvrio. The final net price of $158,000 per year, below the $170,000 price for edaravone, "should enable rapid payer discussions and garner goodwill from physicians/patient advocacy groups, driving rapid uptake in demand and sales recognition," Bitritto-Garg tells investors in a research note. The analyst says continued weakness in the shares on financing overhang and the PHOENIX readout concerns "sets up an attractive upside into initial launch numbers" and European approval. Bitritto-Garg sees a buying opportunity at current Amylyx shared levels.
Citi ups Amylyx target, sees buying opportunity after selloff 10/03 AMLX Citi analyst Neena Bitritto-Garg raised the firm's price target on Amylyx Pharmaceuticals to $50 from $48 and keeps a Buy rating on the shares. The analyst updated her model on full FDA approval for AMX0035, now Relyvrio. The final net price of $158,000 per year, below the $170,000 price for edaravone, "should enable rapid payer discussions and garner goodwill from physicians/patient advocacy groups, driving rapid uptake in demand and sales recognition," Bitritto-Garg tells investors in a research note. The analyst says continued weakness in the shares on financing overhang and the PHOENIX readout concerns "sets up an attractive upside into initial launch numbers" and European approval. Bitritto-Garg sees a buying opportunity at current Amylyx shared levels.